论文部分内容阅读
目的:观察肾康注射液联合脂溶性前列腺素E1对糖尿病肾病的治疗效果。方法:40例糖尿病肾病患者随机分为A、B 2组。A组常规治疗基础上利用肾康注射液40ml联合脂溶性前列腺素E1 10ug每天1次静脉滴注,14天1个疗程。B组予常规治疗,不加肾康注射液联合脂溶性前列腺素E1。结果:A组治疗后尿蛋白明显减少,差异显著(P﹤0.01)而B组治疗前后尿蛋白变化无差异(P﹥0.05)。A、B2组疗效比较差异有显著性(P﹤0.05)。结论:糖尿病肾病临床蛋白尿期,肾康注射液联合脂溶性前列腺素E1对减少蛋白尿有一定疗效。
Objective: To observe the therapeutic effect of Shenkang injection combined with fat-soluble prostaglandin E1 on diabetic nephropathy. Methods: Forty patients with diabetic nephropathy were randomly divided into A and B 2 groups. A group of conventional treatment based on the use of Shen Kang injection 40ml combined with lipolytic prostaglandin E1 10ug daily intravenous infusion of 14 days a course of treatment. B group to conventional treatment, without Shen Kang injection combined with lipophilic prostaglandin E1. Results: Urinary protein in group A decreased significantly (P <0.01), but there was no difference in urine protein before and after treatment in group B (P> 0.05). There was significant difference in the efficacy of A and B2 (P <0.05). Conclusion: The clinical proteinuria of diabetic nephropathy, Shenkang injection combined with lipophilic prostaglandin E1 to reduce proteinuria have a certain effect.